Growth is driven by chronic childhood illness, pediatric-specific and rare-disease therapies, vaccines, precision delivery and digital adherence, with strong opportunities in Asia-Pacific.
Pediatric Drugs Market Pediatric Drugs Market Growth Rate By Regi
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) — The “Global Pediatric Drugs – Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)” report has been added to ResearchAndMarkets.com’s offering.
Pediatric Drugs Market to Reach USD 227.67 Billion by 2031 as Demand for Age-Appropriate Therapies Accelerates
The global pediatric drugs market was valued at USD 141.27 billion in 2025 and is projected to increase from USD 152.97 billion in 2026 to USD 227.67 billion by 2031. The market is expected to expand at a compound annual growth rate of 8.29% during the 2026-2031 forecast period, supported by the rising prevalence of chronic childhood illnesses, expanding pediatric research pipelines, regulatory incentives and growing demand for safer, age-appropriate drug formulations.
Chronic Pediatric Diseases Drive Treatment Demand
The increasing burden of obesity, respiratory disease, neurological conditions, cancer and rare genetic disorders is strengthening demand across the pediatric pharmaceuticals market. Childhood obesity affects approximately 6 million children in the United States, encouraging the development of treatments for younger age groups. Therapies such as liraglutide are now targeting children between the ages of 6 and 12, reflecting the growing need for earlier intervention.
Innovation is also advancing for complex neurological and metabolic conditions. Recent approvals, including KEBILIDI for aromatic L-amino acid decarboxylase deficiency, demonstrate progress in addressing rare pediatric diseases. In pediatric oncology, exosome-based nanocarriers are being studied to improve drug targeting and reduce systemic toxicity. These developments are increasing the need for formulations that provide dose flexibility, long-term safety, improved taste and easier administration.
Research Pipelines Support Pediatric Drug Innovation
Regulatory incentives have helped expand research activity for rare pediatric diseases. The U.S. Food and Drug Administration issued 38 rare pediatric disease priority review vouchers through 2024, while 569 designations were recorded from 2013 onward. Much of this activity has focused on neurology, metabolic disorders and oncology.
Pharmaceutical developers are increasingly designing treatments around pediatric physiology rather than adapting products originally created for adults. Examples include planned regulatory submissions for granule formulations intended for children under 12. This shift toward pediatric-specific drug development is expected to improve treatment adherence, dosing accuracy and clinical outcomes while supporting long-term market growth.
However, pediatric clinical research continues to face ethical and recruitment challenges. Only around 10% of eligible children participate in clinical trials, as parents and caregivers carefully evaluate potential risks. Differences in institutional review procedures and language-related consent barriers can further restrict enrollment, particularly among Black and Hispanic families. Deferred-consent approaches in neonatal studies may help balance urgent treatment requirements with ethical safeguards, although trial complexity is likely to remain a market restraint.
Respiratory Drugs Maintain Leading Market Position
Respiratory disorder treatments accounted for 25.22% of pediatric drugs market revenue in 2025. Demand has remained strong because of corticosteroid dependence, persistent respiratory disease prevalence and shortages involving established therapies. The introduction of albuterol and budesonide combination inhalers is helping reduce supply pressure while providing dual-action treatment options.
Neurology and attention-deficit/hyperactivity disorder drugs are forecast to grow at a CAGR of 8.96% through 2031, driven by improved diagnosis and increasing interest in non-stimulant therapies. Autoimmune and rare disease treatments are also advancing, with therapies such as LENMELDY demonstrating the potential of curative approaches for ultrarare leukodystrophies. Across therapeutic categories, manufacturers are placing greater emphasis on taste, texture, administration convenience and flexible dosing.
North America Leads as Asia-Pacific Records Fastest Growth
North America held 39.85% of the global pediatric drugs market in 2025. The region benefits from established regulatory systems, insurance coverage for specialty formulations and early adoption of advanced healthcare technologies. Priority review activity for products such as XOLREMDI and DUVYZAT has reinforced the region’s role in pediatric drug innovation. Telemedicine and home-based monitoring are also supporting continuity of care, although product shortages have highlighted supply-chain vulnerabilities.
Asia-Pacific is projected to register the fastest regional growth, with a CAGR of 10.32% through 2031. China recorded 895 pediatric clinical trials between 2013 and 2022 and is placing greater emphasis on innovative therapies. India’s USD 250 million partnership with Gavi aims to reduce the number of zero-dose children by 30%, while nationwide pneumococcal vaccination efforts demonstrate the country’s ability to scale pediatric health programs. Japan’s progress in gene therapy approvals further strengthens the region’s position in precision medicine.
Europe is expected to maintain moderate growth, supported by centralized pediatric oversight and evidence-based adoption of new biologics, including respiratory syncytial virus prophylaxis for infants. Opportunities are also emerging in the Middle East, Africa and South America as governments and health organizations work to improve vaccination rates, expand access to essential medicines and strengthen pediatric healthcare infrastructure.
Overall, the pediatric drugs market is positioned for sustained expansion as healthcare systems prioritize childhood disease management and pharmaceutical companies accelerate the development of specialized treatments. Continued progress in rare disease therapies, vaccination, precision medicine and child-friendly formulations will remain central to market growth through 2031.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing burden of chronic pediatric illnesses
4.2.2 Expanding R&D pipelines & pediatric-exclusive designations
4.2.3 Government incentives for orphan & pediatric drugs
4.2.4 Expansion of pediatric vaccination schedules in emerging markets
4.2.5 Real-world evidence accelerating age-appropriate dosing
4.2.6 Digital adherence platforms boosting treatment outcomes
4.3 Market Restraints
4.3.1 Ethical & recruitment hurdles in pediatric trials
4.3.2 High palatability/formulation costs
4.3.3 Antibiotic-stewardship pressure on prescriptions
4.3.4 Supply-chain gaps for taste-masking excipients
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers/Consumers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitute Products
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD Million)
5.1 By Drug Type
5.1.1 Respiratory Disorder Drugs
5.1.2 Autoimmune Disorder Drugs
5.1.3 Gastrointestinal Drugs
5.1.4 Cardiovascular Drugs
5.1.5 Neurology & ADHD Drugs
5.1.6 Oncology Drugs
5.1.7 Other Drug Types
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Topical
5.2.3 Parenteral
5.2.4 Inhalation
5.2.5 Other Routes
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies & Drug Stores
5.3.3 Online Pharmacies
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Pfizer Inc.
6.3.2 Johnson & Johnson (Janssen)
6.3.3 GlaxoSmithKline plc
6.3.4 Sanofi SA
6.3.5 Novartis AG
6.3.6 PTC Therapeutics Inc.
6.3.7 BioMarin Pharmaceutical Inc.
6.3.8 Horizon Therapeutics plc
6.3.9 Jazz Pharmaceuticals plc
6.3.10 Gilead Sciences Inc.
6.3.11 Sumitomo Pharma Co. Ltd.
6.3.12 Boehringer Ingelheim GmbH
6.3.13 F. Hoffmann-La Roche Ltd
6.3.14 Eli Lilly and Company
6.3.15 Amgen Inc.
6.3.16 CSL Seqirus
6.3.17 AstraZeneca plc
6.3.18 Merck & Co., Inc.
6.3.19 AbbVie Inc.
6.3.20 Takeda Pharmaceutical Co.
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/4p3eqo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Pediatric Drugs Market Pediatric Drugs Market Growth Rate By Regi
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
